Faisal Khurshid
Stock Analyst at Leerink Partners
(4.26)
# 436
Out of 5,093 analysts
28
Total ratings
50%
Success rate
23.48%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Maintains: Outperform | $13 → $16 | $12.98 | +23.27% | 2 | Nov 20, 2025 | |
| ABCL AbCellera Biologics | Downgrades: Market Perform | $4 | $3.59 | +11.42% | 2 | Nov 7, 2025 | |
| GLPG Galapagos NV | Upgrades: Outperform | $29 → $40 | $31.49 | +27.02% | 2 | Oct 21, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Outperform | $20 | $12.25 | +63.27% | 1 | Sep 25, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $73 | $90.25 | -19.11% | 1 | Sep 12, 2025 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $3.01 | -33.55% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $105.18 | -3.02% | 2 | Jul 10, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $3.47 | -71.18% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $34.63 | +29.95% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $21.47 | -25.48% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $33 → $2 | $1.28 | +56.25% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $0.81 | +1,869.96% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 | $94.30 | -36.37% | 2 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $81.34 | -1.65% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $3.77 | +297.88% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $16.75 | +168.66% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.27 | +451.18% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $5.63 | +42.10% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.67 | +646.83% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $5.47 | +101.10% | 1 | Mar 21, 2023 |
Trevi Therapeutics
Nov 20, 2025
Maintains: Outperform
Price Target: $13 → $16
Current: $12.98
Upside: +23.27%
AbCellera Biologics
Nov 7, 2025
Downgrades: Market Perform
Price Target: $4
Current: $3.59
Upside: +11.42%
Galapagos NV
Oct 21, 2025
Upgrades: Outperform
Price Target: $29 → $40
Current: $31.49
Upside: +27.02%
Contineum Therapeutics
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $12.25
Upside: +63.27%
Protagonist Therapeutics
Sep 12, 2025
Initiates: Outperform
Price Target: $73
Current: $90.25
Upside: -19.11%
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $3.01
Upside: -33.55%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $105.18
Upside: -3.02%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $3.47
Upside: -71.18%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $34.63
Upside: +29.95%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $21.47
Upside: -25.48%
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.28
Upside: +56.25%
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $0.81
Upside: +1,869.96%
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $94.30
Upside: -36.37%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $81.34
Upside: -1.65%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $3.77
Upside: +297.88%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $16.75
Upside: +168.66%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.27
Upside: +451.18%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $5.63
Upside: +42.10%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.67
Upside: +646.83%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $5.47
Upside: +101.10%